aid: adel97fd
name: ADEL, Inc.
description: >-
  ADEL, Inc. (주식회사 아델) is a clinical-stage biopharmaceutical company headquartered in Seoul,
  South Korea, founded in 2016 as a spin-off from the Asan Medical Center / University of Ulsan
  College of Medicine by Professor Seung-Yong Yoon. ADEL develops antibody therapeutics,
  companion diagnostics and delivery platforms for Alzheimer's disease and other
  neurodegenerative conditions. Its lead candidate ADEL-Y01 is a humanized monoclonal antibody
  selectively targeting tau acetylated at Lysine-280 (acK280), in a global first-in-human Phase 1
  study under a US FDA-cleared IND; in December 2025 ADEL granted Sanofi exclusive worldwide
  rights to ADEL-Y01 in a deal worth up to USD 1.04 billion including an USD 80 million upfront
  payment. The wider pipeline includes ADEL-Y03 (a beta-2 microglobulin antibody), ADEL-Y04 (an
  ApoE4-targeting antibody), the ADEL-D01 tau pT217 diagnostic antibody, and two proprietary
  platforms — BTS (Brain Targeting System) for blood-brain-barrier penetration and ADTAC
  (Autophagic Degradation Targeting Chimera) for targeted protein degradation. The company is
  research-and-development driven and sells no software product: it publishes no developer
  portal, public API, SDK, webhook catalog or machine-readable specification of any kind. Its
  only web surface is the corporate marketing site at adelpharm.com.
url: https://raw.githubusercontent.com/api-evangelist/adel97fd/refs/heads/main/apis.yml
x-harvest-source-url: https://equityzen.com/company/adel97fd
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: not-a-software-company
x-founded: '2016'
x-headquarters: Seoul, South Korea
x-industry: Biotechnology / Pharmaceuticals
x-identity-note: >-
  The harvest stub carried the placeholder name "Adel97fd", taken verbatim from the EquityZen
  slug. The 97fd suffix matches Crunchbase's adel-97fd, and the EquityZen listing page title is
  "Invest In ADEL Stock"; both resolve to ADEL, Inc., the Korean Alzheimer's antibody developer
  at adelpharm.com. EquityZen classifies the company under "Software, Artificial Intelligence,
  Data and Analytics", which is a venue mis-tag — EquityZen's own body copy on the same page
  describes a therapeutics and diagnostics developer, and every independent source (BioSpace,
  Fierce Biotech, Korea Biomedical Review, BIO International Convention, PitchBook, Preqin)
  records a clinical-stage biopharmaceutical company.
x-domain-note: >-
  adelpharm.com (created 2018-05-15, registrar Whois Corp.), adelbio.com (created 2026-08-28,
  registrar Gabia) and adelbio.co.kr all resolve to the same Cafe24 origin 183.111.183.82 and
  share the Cafe24 nameservers ns1/ns2.cafe24.co.kr and .com, so all three are the same
  first-party surface. Every host answers HTTP 200 to EVERY path with an identical
  JavaScript-decryption WAF interstitial (a slowAES "cupid.js" challenge that sets a CUPID
  cookie and reloads with ?ckattempt=1), including a random negative-control path that cannot
  exist. No path on any host returns a document to a non-browser client. See
  well-known/adel97fd-well-known.yml.
x-venue-note: >-
  The harvest source https://equityzen.com/company/adel97fd is an EquityZen secondary-market
  listing, not ADEL's own web presence, and is deliberately NOT wired as the Website pointer
  (roadmap#56). It is recorded as a SecondaryMarket property instead.
specificationVersion: '0.23'
created: '2026-09-07'
modified: '2026-09-07'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Healthcare
- Drug Discovery
- Antibody Therapeutics
- Neuroscience
- Alzheimers Disease
- Clinical Trials
- Diagnostics
- South Korea
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Healthcare
- Drug Discovery
- Antibody Therapeutics
- Neuroscience
- Alzheimers Disease
- Clinical Trials
- Diagnostics
- South Korea
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/adel97fd-domain-security.yml
- type: Website
  name: ADEL corporate site (English)
  url: https://adelpharm.com/en/
- type: SecondaryMarket
  name: EquityZen pre-IPO listing (third-party venue, not an ADEL page)
  url: https://equityzen.com/company/adel97fd
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    ADEL is a clinical-stage antibody developer whose product is a drug, not software — its only
    web surface is the adelpharm.com corporate marketing site (company, pipeline, technology,
    news, contact), and that site sits behind a Cafe24 "cupid.js" JavaScript-decryption WAF that
    answers HTTP 200 with the same interstitial to all 120 probed paths across all six
    first-party hosts, including a random negative-control path, so no document — spec,
    well-known, llms.txt or agent card — was retrievable and none is documented to exist.
  evidence:
  - url: https://adelpharm.com/.well-known/adel97fd-negative-control-7c3e91a2.json
    status: 200
  - url: https://adelpharm.com/openapi.json
    status: 200
  - url: https://adelpharm.com/.well-known/agent-card.json
    status: 200
  - url: https://adelbio.com/llms.txt
    status: 200
  - url: https://api.github.com/orgs/adelpharm
    status: 404
  - url: https://equityzen.com/company/adel97fd
    status: 200
  checked: '2026-09-07'
x-enrichment:
  date: '2026-09-07'
  status: minimal
  artifacts_added: 2
  pass: local-v3